Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F19%3A00519621" target="_blank" >RIV/61388963:_____/19:00519621 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190917&DB=&locale=en_EP&CC=US&NR=10414788B2&KC=B2&ND=4#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190917&DB=&locale=en_EP&CC=US&NR=10414788B2&KC=B2&ND=4#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
Original language description
A group of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, in which R shows strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
US10414788
Publisher
US001 -
Publisher name
United States Patent and Trademark Office (USPTO)
Place of publication
Alexandria
Publication country
US - UNITED STATES
Date of acceptance
Sep 17, 2019
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i. - Univerzita Palackého v Olomouci
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence